Cargando…

Clinical response to belimumab in academic clinical practices

Detalles Bibliográficos
Autores principales:	Reddy, Arthi, Li, XiaoQing, Buyon, Jill P, Franks, Andrew G, Furie, Richard A, Kamen, Diane L, Manzi, Susan, Petri, Michelle, Ramsey-Goldman, Rosalind, Tseng, Chung-E, van Vollenhoven, Ronald F, Wallace, Daniel J, Askanase, Anca D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179583/ http://dx.doi.org/10.1186/ar4665

Ejemplares similares

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Thoughts on COVID-19 and autoimmune diseases
por: Askanase, Anca D, et al.
Publicado: (2020)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue
por: Buyon, Jill, et al.
Publicado: (2014)

Editorial
por: Buyon, Jill, et al.
Publicado: (2014)

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
por: Petri, Michelle, et al.
Publicado: (2023)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
por: Plüß, Marlene, et al.
Publicado: (2020)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
por: Manzi, Susan, et al.
Publicado: (2012)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
por: Ferreira, Isabel, et al.
Publicado: (2017)

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
por: Teng, Y K Onno, et al.
Publicado: (2019)

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2020)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
por: Bruce, I N, et al.
Publicado: (2016)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
por: Mendel, Arielle, et al.
Publicado: (2019)

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Lupus clinical trials and the promise of future therapies
por: Khalili, Leila, et al.
Publicado: (2023)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
por: Wu, Chunye, et al.
Publicado: (2022)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data
por: Wallace, Daniel J, et al.
Publicado: (2022)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mhsiv29o667mlbu2r4ks7okucd